295 related articles for article (PubMed ID: 25894587)
1. Hepcidin-25 in diabetic chronic kidney disease is predictive for mortality and progression to end stage renal disease.
Wagner M; Ashby DR; Kurtz C; Alam A; Busbridge M; Raff U; Zimmermann J; Heuschmann PU; Wanner C; Schramm L
PLoS One; 2015; 10(4):e0123072. PubMed ID: 25894587
[TBL] [Abstract][Full Text] [Related]
2. Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney disease.
Wagner M; Alam A; Zimmermann J; Rauh K; Koljaja-Batzner A; Raff U; Wanner C; Schramm L
Clin J Am Soc Nephrol; 2011 Jul; 6(7):1573-9. PubMed ID: 21734083
[TBL] [Abstract][Full Text] [Related]
3. Hepcidin and proinflammatory markers in children with chronic kidney disease: A case-control study
.
Goyal KK; Saha A; Sahi PK; Kaur M; Dubey NK; Goyal P; Upadhayay AD
Clin Nephrol; 2018 May; 89(5):363-370. PubMed ID: 29451472
[TBL] [Abstract][Full Text] [Related]
4. Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: a prospective cohort study.
Fujita Y; Doi Y; Hamano T; Hatazaki M; Umayahara Y; Isaka Y; Tsubakihara Y
Sci Rep; 2019 Oct; 9(1):14871. PubMed ID: 31619722
[TBL] [Abstract][Full Text] [Related]
5. The Hepcidin-Anemia Axis: Pathogenesis of Anemia in Chronic Kidney Disease.
Nakanishi T; Kimura T; Kuragano T
Contrib Nephrol; 2019; 198():124-134. PubMed ID: 30991414
[TBL] [Abstract][Full Text] [Related]
6. Iron-hepcidin dysmetabolism, anemia and renal hypoxia, inflammation and fibrosis in the remnant kidney rat model.
Garrido P; Ribeiro S; Fernandes J; Vala H; Bronze-da-Rocha E; Rocha-Pereira P; Belo L; Costa E; Santos-Silva A; Reis F
PLoS One; 2015; 10(4):e0124048. PubMed ID: 25867633
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of stage 1-5 chronic kidney disease in Mainland China.
Lai X; Zhang AH; Chen SY; He L; Su CY; Fan MH; Wang T
Ren Fail; 2014 May; 36(4):520-5. PubMed ID: 24456114
[TBL] [Abstract][Full Text] [Related]
8. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.
Uehata T; Tomosugi N; Shoji T; Sakaguchi Y; Suzuki A; Kaneko T; Okada N; Yamamoto R; Nagasawa Y; Kato K; Isaka Y; Rakugi H; Tsubakihara Y
Nephrol Dial Transplant; 2012 Mar; 27(3):1076-83. PubMed ID: 21799206
[TBL] [Abstract][Full Text] [Related]
9. Progression and outcomes of non-dialysis dependent chronic kidney disease patients: A single center longitudinal follow-up study.
Khan YH; Sarriff A; Adnan AS; Khan AH; Mallhi TH; Jummaat F
Nephrology (Carlton); 2017 Jan; 22(1):25-34. PubMed ID: 26718476
[TBL] [Abstract][Full Text] [Related]
10. C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Mc Causland FR; Claggett B; Burdmann EA; Eckardt KU; Kewalramani R; Levey AS; McMurray JJ; Parfrey P; Remuzzi G; Singh AK; Solomon SD; Toto RD; Pfeffer MA
Am J Kidney Dis; 2016 Dec; 68(6):873-881. PubMed ID: 27646425
[TBL] [Abstract][Full Text] [Related]
11. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD.
Desai AS; Toto R; Jarolim P; Uno H; Eckardt KU; Kewalramani R; Levey AS; Lewis EF; McMurray JJ; Parving HH; Solomon SD; Pfeffer MA
Am J Kidney Dis; 2011 Nov; 58(5):717-28. PubMed ID: 21820220
[TBL] [Abstract][Full Text] [Related]
12. Acute-Phase Proteins and Iron Status in Cats with Chronic Kidney Disease.
Javard R; Grimes C; Bau-Gaudreault L; Dunn M
J Vet Intern Med; 2017 Mar; 31(2):457-464. PubMed ID: 28140480
[TBL] [Abstract][Full Text] [Related]
13. Characterization of erythropoietin and hepcidin in the regulation of persistent injury-associated anemia.
Alamo IG; Kannan KB; Smith MA; Efron PA; Mohr AM
J Trauma Acute Care Surg; 2016 Oct; 81(4):705-12. PubMed ID: 27398985
[TBL] [Abstract][Full Text] [Related]
14. Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study.
Eisenga MF; De Jong MA; Van der Meer P; Leaf DE; Huls G; Nolte IM; Gaillard CAJM; Bakker SJL; De Borst MH
PLoS Med; 2019 Jun; 16(6):e1002818. PubMed ID: 31170159
[TBL] [Abstract][Full Text] [Related]
15. Elderly patients with chronic kidney disease: outcomes after 5 years of follow-up.
Heras M; Fernández-Reyes MJ; Sánchez R; Guerrero MT; Molina A; Rodríguez MA; Alvarez-Ude F
Nefrologia; 2012 May; 32(3):300-5. PubMed ID: 22508140
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance as a predictor of cardiovascular morbidity and end-stage renal disease.
Fragoso A; Mendes F; Silva AP; Neves PL
J Diabetes Complications; 2015; 29(8):1098-104. PubMed ID: 26066409
[TBL] [Abstract][Full Text] [Related]
17. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia.
Landau D; London L; Bandach I; Segev Y
PLoS One; 2018; 13(5):e0196684. PubMed ID: 29738538
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of proteinuria and glomerular filtration rate on Taiwanese patients with diabetes mellitus and advanced chronic kidney disease: a single center experience.
Chen PM; Wada T; Chiang CK
Clin Exp Nephrol; 2017 Apr; 21(2):307-315. PubMed ID: 27339442
[TBL] [Abstract][Full Text] [Related]
19. Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond.
Ueda N; Takasawa K
Curr Med Chem; 2017; 24(14):1417-1452. PubMed ID: 28302014
[TBL] [Abstract][Full Text] [Related]
20. Serum hepcidin-25 levels predict the progression of renal anemia in patients with non-dialysis chronic kidney disease.
Niihata K; Tomosugi N; Uehata T; Shoji T; Mitsumoto K; Shimizu M; Kawabata H; Sakaguchi Y; Suzuki A; Hayashi T; Okada N; Isaka Y; Rakugi H; Tsubakihara Y
Nephrol Dial Transplant; 2012 Dec; 27(12):4378-85; discussion 4384-5. PubMed ID: 22833619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
